LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aktien・Tandem Diabetes Care Inc

Tandem Diabetes Care Inc

Geschlossen

BrancheGesundheitswesen

14.82 1.72

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.99

Max

14.98

Schlüsselkennzahlen
By Trading Economics
Einkommen	-20M -20M
Verkäufe	-43M 247M
EPS	-0.3
Gewinnspanne	-8.249
Angestellte	2,500
EBITDA	-29M -17M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+117.13% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-336M 1B
Vorheriger Eröffnungskurs	13.1
Vorheriger Schlusskurs	14.82

Nachrichtenstimmung

By Acuity

25%

75%

39 / 344 Ranking in Healthcare

Tandem Diabetes Care Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Tandem Diabetes Care Inc Prognose

Kursziel

By TipRanks

117.13% Vorteil

12-Monats-Prognose

Durchschnitt 31.57 USD 117.13%

Hoch 55 USD

Tief 21 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Tandem Diabetes Care Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

Buy

Halten

Sell

Basierend auf 15 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Tandem Diabetes Care Inc – Dist abgegeben haben.

Stimmung

By Acuity

39 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.